018680 — Seoul Pharma Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-1,342	-9,689	855	3,517	1,699
Depreciation
Amortisation
Non-Cash Items	6,349	5,622	2,159	2,314	1,584
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1,714	-136	-5,705	-2,495	-8,781
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	5,737	-1,675	-78.2	5,265	-3,008
Capital Expenditures	-671	-1,168	-1,299	-1,894	-2,230
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	378	68.2	-33	-3,968	3,687
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-293	-1,099	-1,332	-5,862	1,457
Financing Cash Flow Items	-0.722	0	-8.94	0	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Debt
Cash from Financing Activities	2,005	1,535	-483	-4,466	2,380
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	7,392	-1,237	-2,092	-5,155	966